<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080076</url>
  </required_header>
  <id_info>
    <org_study_id>NN-002</org_study_id>
    <nct_id>NCT04080076</nct_id>
  </id_info>
  <brief_title>Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy</brief_title>
  <acronym>FACT</acronym>
  <official_title>A Multicenter Comparative Safety and Efficacy Study of ACTHar Gel Alone or in Combination With Oral Tacrolimus to Reduce Urinary Proteinuria in Patients With Idiopathic DNAJB9 Positive Fibrillary Glomerulopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NephroNet, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NephroNet, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 1 treatment ACTHar gel
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, Phase 4, prospective, open labeled study to compare the safety,
      tolerability, and efficacy of a 12month course of ACTHar The addition of tacrolimus to
      patients exhibiting a partial response to ACTH resulted in a further reduction in Fibrillary
      glomerulopathy.

      :

      Spe #1-will randomize with biopsy proven DNA-JB9 positive Fibrillary glomerulopathy to
      receive course of ACTHar gel at 80 units SQ 2X/week alone or in combination with oral
      Tacrolimus at 1.0 mg BID (targeting for trough Tacrolimus dose o

      Hypothesis Treatment with combination ACTHar gel therapy will result in a higher eGFR after
      24 months of follow up than patients randomized to ACTHar gel therapy alone

      Hy3: Combination therapy of ACTHar Gel and Tacrolimus in patients with DNA-JB9 positive
      Fibrillary will lead to significantly lower urinary markers of podocyte injury compared t
      ACTHar gel therapy alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2019</start_date>
  <completion_date type="Anticipated">March 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>ACTHar gel alone-patients will be receive 80 units SQ Q 2X/week for 52 weeks
ACTH gel 80 units 2X per week plus oral Tacrolimus (1.0 mg BID) titrating to a trough level of 4-6 ng/ml for 52 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in UP/Cr ratio in patients with biopsy proven Fibrillary GN after treated with ACTHar gel alone OR in combination with oral Tacrolimus</measure>
    <time_frame>12 months</time_frame>
    <description>The change in UP/Cr ratio in patients with biopsy proven Fibrillary GN after 12 months of treatment with treated with ACTHar gel (80 units SQ 2X/week) alone OR in combination with oral Tacrolimus (1.0 mg PO BID). The change in UP/Cr for each group will also be compared to baseline UP/Cr ratios prior to randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relative change in UP/Cr</measure>
    <time_frame>24 months</time_frame>
    <description>The relative change in UP/Cr at 24 months (12 months after stopping both ACTH and Tacrolimus) in the ACTHar gel group and the ACTHar gel + Tacrolimus group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T that achieves complete, partial or clinical responses</measure>
    <time_frame>12 months</time_frame>
    <description>The percentage of patients in the ACTHar gel alone versus ACTHar gel + Tacrolimus group that achieves complete, partial or clinical responses after 12 months of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in eGFR (measured by CKD-EPI formula) between the ACTHar gel and ACTHar Gel + Tacrolimus groups</measure>
    <time_frame>24 months</time_frame>
    <description>The change in eGFR (measured by CKD-EPI formula) between the ACTHar gel and ACTHar Gel + Tacrolimus groups after 24 months of treatment with ACTHar gel alone or in combination with oral Tacrolimus. In addition, we will also compare the relative change in eGFR between those patients receiving ACTHar gel alone with those randomized to combination therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the change in urinary biomarkers with ACTHar gel alone or in combination with Tacrolimus.</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the change in urinary biomarkers (see below) at baseline and after 12 months of treatment with ACTHar gel alone or in combination with Tacrolimus. The patients urinary biomarker levels after 12 months of therapy will be compared between the ACTHar gel alone group and ACTHar gel + Tacrolimus group. a) Urinary VEGF 121, 165 189, and206 b) Urinary MCP-1 c) Urinary Synaptopodin d) Urinary TGF-beta e) Urinary Podocalyxin f) Urinary Nephrin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Renal Disease</condition>
  <condition>Fibrillary Glomerulopathy</condition>
  <arm_group>
    <arm_group_label>ACTHar gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACTHar gel alone-patients will be receive 80 units SQ Q 2X/week for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACTHar gel combined with Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACTH gel 80 units 2X per week plus oral Tacrolimus (1.0 mg BID) titrating to a trough level of 4-6 ng/ml for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar 80 UNT/ML Injectable Solution</intervention_name>
    <description>ACTHar 80 Units SQ 42 x Week</description>
    <arm_group_label>ACTHar gel</arm_group_label>
    <arm_group_label>ACTHar gel combined with Tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Tab Tacrolimus</intervention_name>
    <description>Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 42 X week</description>
    <arm_group_label>ACTHar gel combined with Tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Histologic Inclusion Criteria:

        All patients with a diagnosis of The Fibrillary GN will be classified according to the Nasr
        nomenclature:

          1. Renal biopsy demonstrating DNA-JB9 Positive staining within 3 years of study
             randomization

          2. Mesangial expansion with/without glomerular sclerosis diffuse sclerosis

        4) Crescents or endocapillary proliferation Note: Patients with &gt; 50% interstitial fibrosis
        will not be eligible for study Note: Patients with monoclonal will not be eligible for
        study participation

        Inclusion Criteria:

          1. Male/Female ag

          2. Biopsy proven Fibrillary GN wityears of study randomization

          3. Stable Maximum RAAS inhibition X 4 weeks prior to randomization Note: Maximum RAAS
             inhibition will be the discretion of the site PI

          4. eGFR &gt; 25 mls/min calculate b formula

          5. UP/Cr ratio &gt; 2000 mg/gm 5 Note: IF UP/Cr less than 2000 mg/gm, a formal urine
             collection for total protein can be performed. The total 24-hour will need to &gt;/=
             2000mg.

          6. Blood pressure targeted to &lt; 140/90 at the time of randomization

          7. Patients with MGUS without history of myeloma WILL be eligible.

          8. Patients with monoclonal staining for fibrillary fibers will be excluded

          9. Patients with Type II non-insulin dependent diabetes WILL be eligible provided the
             renal biopsy does not show nodular Kimmelstiel Wilson lesions

        Exclusion

          1. Patients with MGUS and history of myeloma WILL NOT be eligible

          2. Patients with active viral production of either B or C as evidence by historical PCR
             test positive for active viral shedding

          3. HIV seropositivity

          4. Renal biopsy data with &gt; 50% Interstitial Fibrosis

          5. Patient with active or a known history

          6. Patients with insulin Dependent diabetes mellitus will be excluded Note: patients with
             T are well controlled WITHOUT the need for insulin WILL be eligible for the study.

          7. Patients with Type II non-insulin dependent diabetes WILL be eligible provided the
             renal biopsy does not show nodular Kimmelstiel Wilson lesions.

          8. Patients receiving steroids, MMF, cyc, Azathioprine or other immunosuppressive agent
             with of study random Note: Wash medications will be allowed at the screening visit

          9. Patients having received Rituximab or B cell modifying biologic therapy within 6
             months of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A. Tumlin, MD</last_name>
    <role>Study Director</role>
    <affiliation>NephroNet, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James A. Tumlin, MD</last_name>
    <phone>770-490-9333</phone>
    <email>jamestumlinmdnephronet@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy Whitson, CCRA, CCRP</last_name>
    <email>jwhitson@nephrosynergy.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgia Nephrology Research Institute</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James A Tumlin, MD, CCRP</last_name>
      <phone>770-490-5555</phone>
      <email>jamestumlinmdnephronet@gmai.com</email>
    </contact>
    <contact_backup>
      <last_name>Jeremy Whitson, CCRA, CCRP</last_name>
      <phone>424-943-4265</phone>
      <phone_ext>4239434265</phone_ext>
      <email>jwhitson@synergy.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sethi S, Theis JD, Vrana JA, Fervenza FC, Sethi A, Qian Q, Quint P, Leung N, Dogan A, Nasr SH. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol. 2013 Jun;8(6):915-21. doi: 10.2215/CJN.07030712. Epub 2013 Feb 14.</citation>
    <PMID>23411427</PMID>
  </reference>
  <reference>
    <citation>Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, Leung N, Fervenza FC. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol. 2011 Apr;6(4):775-84. doi: 10.2215/CJN.08300910. Epub 2011 Mar 24.</citation>
    <PMID>21441134</PMID>
  </reference>
  <reference>
    <citation>Alpers CE, Kowalewska J. Fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol. 2008 Jan;19(1):34-7. Epub 2007 Nov 28.</citation>
    <PMID>18045849</PMID>
  </reference>
  <reference>
    <citation>Pliquett RU, Mohr P, El Din Mukhtar B, Girndt M, Markau S. Plasmapheresis leading to remission of refractory nephrotic syndrome due to fibrillary glomerulonephritis: a case report. J Med Case Rep. 2012 Apr 24;6:116. doi: 10.1186/1752-1947-6-116.</citation>
    <PMID>22531147</PMID>
  </reference>
  <reference>
    <citation>Hogan J, Restivo M, Canetta PA, Herlitz LC, Radhakrishnan J, Appel GB, Bomback AS. Rituximab treatment for fibrillary glomerulonephritis. Nephrol Dial Transplant. 2014 Oct;29(10):1925-31. doi: 10.1093/ndt/gfu189. Epub 2014 May 27.</citation>
    <PMID>24867652</PMID>
  </reference>
  <reference>
    <citation>Collins M, Navaneethan SD, Chung M, Sloand J, Goldman B, Appel G, Rovin BH. Rituximab treatment of fibrillary glomerulonephritis. Am J Kidney Dis. 2008 Dec;52(6):1158-62. doi: 10.1053/j.ajkd.2008.07.011. Epub 2008 Sep 27.</citation>
    <PMID>18823685</PMID>
  </reference>
  <reference>
    <citation>González-Cabrera F, Henríquez-Palop F, Ramírez-Puga A, Santana-Estupiñán R, Plaza-Toledano C, Antón-Pérez G, Marrero-Robayna S, Ramírez-Medina D, Gallego-Samper R, Vega-Díaz N, Camacho-Galan R, Rodríguez-Pérez JC. The occurrence or fibrillary glomerulonephritis in patients with diabetes mellitus may not be coincidental: a report of four cases. Case Rep Med. 2013;2013:935172. doi: 10.1155/2013/935172. Epub 2013 May 20.</citation>
    <PMID>23762079</PMID>
  </reference>
  <reference>
    <citation>Tumlin JA, Galphin CM, Rovin BH. Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1. J Diabetes Res. 2013;2013:489869. doi: 10.1155/2013/489869. Epub 2013 Sep 12.</citation>
    <PMID>24159603</PMID>
  </reference>
  <reference>
    <citation>Korbet SM, Schwartz MM, Lewis EJ. Immuotactoid glomerulopathy (fibrillary glomerulonephritis). Clin J Am Soc Nephrol. 2006 Nov;1(6):1351-6. Epub 2006 Sep 13.</citation>
    <PMID>17699368</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

